CN102224135A - 用作皮质儿茶酚胺能神经传递调节剂的新3-苯基-氮杂环丁烷衍生物 - Google Patents

用作皮质儿茶酚胺能神经传递调节剂的新3-苯基-氮杂环丁烷衍生物 Download PDF

Info

Publication number
CN102224135A
CN102224135A CN2009801464443A CN200980146444A CN102224135A CN 102224135 A CN102224135 A CN 102224135A CN 2009801464443 A CN2009801464443 A CN 2009801464443A CN 200980146444 A CN200980146444 A CN 200980146444A CN 102224135 A CN102224135 A CN 102224135A
Authority
CN
China
Prior art keywords
phenyl
steric isomer
mixture
obstacle
oxide compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801464443A
Other languages
English (en)
Chinese (zh)
Inventor
C·索内松
L·斯万松
F·彼德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NSAB Filial af Neurosearch Sweden AB
Original Assignee
NSAB Filial af Neurosearch Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NSAB Filial af Neurosearch Sweden AB filed Critical NSAB Filial af Neurosearch Sweden AB
Publication of CN102224135A publication Critical patent/CN102224135A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801464443A 2008-11-24 2009-11-24 用作皮质儿茶酚胺能神经传递调节剂的新3-苯基-氮杂环丁烷衍生物 Pending CN102224135A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200801656 2008-11-24
DKPA200801656 2008-11-24
US11781808P 2008-11-25 2008-11-25
US61/117,818 2008-11-25
PCT/EP2009/065675 WO2010058017A1 (en) 2008-11-24 2009-11-24 Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

Publications (1)

Publication Number Publication Date
CN102224135A true CN102224135A (zh) 2011-10-19

Family

ID=41649970

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801464443A Pending CN102224135A (zh) 2008-11-24 2009-11-24 用作皮质儿茶酚胺能神经传递调节剂的新3-苯基-氮杂环丁烷衍生物

Country Status (8)

Country Link
US (1) US8586572B2 (enExample)
EP (1) EP2367785B1 (enExample)
JP (1) JP5621087B2 (enExample)
CN (1) CN102224135A (enExample)
AU (1) AU2009317155A1 (enExample)
CA (1) CA2744307A1 (enExample)
MX (1) MX2011005034A (enExample)
WO (1) WO2010058017A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107646031A (zh) * 2015-05-20 2018-01-30 综合研究实验室瑞典股份公司 用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物
CN109963834A (zh) * 2016-11-18 2019-07-02 综合研究实验室瑞典股份公司 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402713T3 (es) 2008-11-24 2013-05-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Derivados de 3-fenilo-3-metoxipirrolidina como moduladores de la transmisión catecolaminérgica cortical

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1236078A (en) * 1968-07-04 1971-06-16 Beecham Group Ltd Substituted azetidinols
GB1266587A (enExample) * 1968-06-28 1972-03-15
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
WO2005026153A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinazoline-2, 4-diones as antibacterial agents
CN1902169A (zh) * 2003-11-10 2007-01-24 迈克罗比亚公司 4－联芳基－1－苯基氮杂环丁烷－2－酮
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481920A (en) * 1965-10-22 1969-12-02 Lilly Co Eli Azetidinones
US3668196A (en) * 1965-10-22 1972-06-06 Lilly Co Eli 3-azetidinols
US3822252A (en) 1968-06-28 1974-07-02 Schering Corp 3-azetidinols
US3494964A (en) 1969-01-13 1970-02-10 Lilly Co Eli Alpha-halo-alpha-amino ketones
EP1049670B1 (en) * 1998-01-23 2002-07-17 Vernalis Research Limited Azetidinecarboxamide derivatives for treating cns disorders
GB9917384D0 (en) * 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-III
WO2005026146A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Azetidinyl quinolones as antibacterial agents
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
JP2008543828A (ja) 2005-06-15 2008-12-04 ファイザー・リミテッド ドーパミン作動薬としての３−フェニルアゼチジン誘導体
ATE508110T1 (de) 2007-06-05 2011-05-15 Nsab Af Neurosearch Sweden Ab Neue disubstituierte phenylpyrrolidine als modulatoren der kortikalen katecholaminergen neurotransmission
BRPI0812740A2 (pt) 2007-06-05 2016-07-19 Nsab Af Neurosearch Sweden Ab composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
US20110257148A1 (en) 2008-11-24 2011-10-20 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Novel 1-alkyl-3-hydroxy-3-phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
ES2402713T3 (es) 2008-11-24 2013-05-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Derivados de 3-fenilo-3-metoxipirrolidina como moduladores de la transmisión catecolaminérgica cortical

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1266587A (enExample) * 1968-06-28 1972-03-15
GB1236078A (en) * 1968-07-04 1971-06-16 Beecham Group Ltd Substituted azetidinols
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
WO2005026153A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinazoline-2, 4-diones as antibacterial agents
CN1902169A (zh) * 2003-11-10 2007-01-24 迈克罗比亚公司 4－联芳基－1－苯基氮杂环丁烷－2－酮
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JANE BROWN，等: "New functionalised silicas for highly selective cation exchange SPE purification in medicinal chemistry", 《TETRAHEDRON LETTERS》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107646031A (zh) * 2015-05-20 2018-01-30 综合研究实验室瑞典股份公司 用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物
CN107646031B (zh) * 2015-05-20 2020-11-17 综合研究实验室瑞典股份公司 用作皮质儿茶酚胺能神经传递调节剂的氮杂环丁烷衍生物
CN109963834A (zh) * 2016-11-18 2019-07-02 综合研究实验室瑞典股份公司 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物
CN109963834B (zh) * 2016-11-18 2023-04-14 综合研究实验室瑞典股份公司 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物

Also Published As

Publication number Publication date
JP5621087B2 (ja) 2014-11-05
WO2010058017A1 (en) 2010-05-27
US8586572B2 (en) 2013-11-19
EP2367785A1 (en) 2011-09-28
US20110281835A1 (en) 2011-11-17
CA2744307A1 (en) 2010-05-27
MX2011005034A (es) 2011-06-16
EP2367785B1 (en) 2014-10-15
JP2012509860A (ja) 2012-04-26
AU2009317155A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
US9035073B2 (en) 3-phenyl-3-methoxy-pyrrolidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CN102015674B (zh) 多巴胺神经传递调节剂
EP2367786B1 (en) Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CN102224135A (zh) 用作皮质儿茶酚胺能神经传递调节剂的新3-苯基-氮杂环丁烷衍生物
EP3297987B1 (en) Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
HK1245251A1 (en) Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
HK1162172A (en) Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
HK1162173B (en) 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1162172

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111019

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1162172

Country of ref document: HK